Abstract:<h3 class="Heading">Rationale</h3><p class="Para">Exposure to chronic constant light (CCL) has a detrimental impact on circadian rhythms of motor activity and sleep/wake cycles. Agomelatine is an atypical antidepressant showing a chronotropic activity.</p><h3 class="Heading">Objectives</h3><p class="Para">In this study, we explored the role of melatonin (MT) receptors and brain-derived neurotrophic factor (BDNF) in the brain in the mechanism underlying the effects of agomelatine on diurnal variations of motor activity, sleep/wake cycle, and sleep architecture in a rat model of CCL.</p><h3 class="Heading">Methods</h3><p class="Para">In <em class="EmphasisTypeItalic">Experiment #1</em>, home cage activity was monitored automatically with cameras for a period of 24 h. The diurnal rhythm of MT<sub>1,</sub> MT<sub>2</sub> receptors, and BDNF expression in the hippocampus and frontal cortex (FC), was tested using the ELISA test. In <em class="EmphasisTypeItalic">Experiment #2</em>, rats were equipped with electroencephalographic (EEG) and electromyographic (EMG) electrodes and recordings were made under basal conditions (12:12 LD cycle + vehicle), LL + vehicle and LL + agomelatine (40 mg/kg/day for 21 days).</p><h3 class="Heading">Results</h3><p class="Para">The rats exposed to CCL showed an impaired diurnal rhythm of motor activity and sleep/wake cycle with reduced NREM sleep and <em class="EmphasisTypeItalic">delta</em> power and increased REM sleep and <em class="EmphasisTypeItalic">theta</em> power. The duration and number of episodes of the wake were diminished during the subjective dark phase in this group. The circadian rhythm of MT<sub>1</sub> and MT<sub>2</sub> receptors and their expression did not change in the hippocampus and FC under CCL exposure, while the BDNF levels in the hippocampus decreased during the subjective light phase. Agomelatine restored the diurnal rhythm of motor activity, disturbed sleep/wake cycle, and sleep architecture, which effect was accompanied by an increase in MT<sub>1</sub> receptor and BDNF expression in the hippocampus at 10:00 in CCL rats.</p><h3 class="Heading">Conclusions</h3><p class="Para">These findings support the value of agomelatine as an antidepressant that can adjust circadian homeostasis of motor activity and sleep/wake cycle in a CCL model.</p>

The effects of agomelatine on endoplasmic reticulum stress related to mitochondrial dysfunction in hippocampus of aging rat model

Agomelatine Prevents Amyloid Plaque Deposition, Tau Phosphorylation, and Neuroinflammation in APP/PS1 Mice

Oxymatrine ameliorates agomelatine-induced hepatocyte injury through promoting proteasome-mediated CHOP degradation

Agomelatine: a potential novel approach for the treatment of memory disorder in neurodegenerative disease

Melatonin Receptor Stimulation by Agomelatine Prevents Aβ-induced Tau Phosphorylation and Oxidative Damage in PC12 Cells

Effects of agomelatine on behaviour, circadian expression of period 1 and period 2 clock genes and neuroplastic markers in the predator scent stress rat model of PTSD

Effects of agmatine on cognitive functions during vascular dementia in biological aging through eNOS and BDNF expression

Effects of agomelatine on pentylenetetrazole-induced kindling, kindling-associated oxidative stress, and behavioral despair in mice and modulation of its actions by luzindole and 1-(m-chlorophenyl) piperazine

Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats

Citrate‐coated silver nanoparticles loaded with agomelatine provide neuronal therapy in acute cerebral ischemia/reperfusion of rats by inhibiting the oxidative stress, endoplasmic reticulum stress, and P2X7 receptor‐mediated inflammasome

Protective Effect of the Novel Melatonin Analogue Containing Donepezil Fragment on Memory Impairment via MT/ERK/CREB Signaling in the Hippocampus in a Rat Model of Pinealectomy and Subsequent Aβ1-42 Infusion

Agomelatine prevented depression in the chronic restraint stress model through enhanced catalase activity and halted oxidative stress

Long-term oral melatonin alleviates memory deficits, reduces amyloid-β deposition associated with downregulation of BACE1 and mitophagy in APP/PS1 transgenic mice

Nicotinamide Mononucleotide and Melatonin Alleviate Aging-induced Cognitive Impairment via Modulation of Mitochondrial Function and Apoptosis in the Prefrontal Cortex and Hippocampus

A Novel Melatonin Agonist Neu-P11 Facilitates Memory Performance and Improves Cognitive Impairment in A Rat Model of Alzheimer' Disease

Melatonin protects against amyloid-β-induced impairments of hippocampal LTP and spatial learning in rats

Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT1 receptor as well as BDNF expression in the hippocampus during the subjective light phase of rats exposed to chronic constant light

Melatonin improves cognitive dysfunction and decreases gliosis in the streptozotocin-induced rat model of sporadic Alzheimer's disease

Agomelatine promotes differentiation of oligodendrocyte precursor cells and preserves white matter integrity after cerebral ischemic stroke

Agomelatine protects hippocampal neurons against doxorubicin induced toxicity

Deregulation of Melatonin Receptors and Differential Modulation of After‐Hyperpolarization and Ih Currents Using Melatonin Treatment Due to Amyloid‐β‐Induced Neurotoxicity in the Hippocampus